Meet the Professors
Hover over speaker photo to view profile
Meet the Professor breakfast sessions allow delegates to meet in a small group with renowned researchers and clinicians. The format is designed to facilitate informal discussions, allowing participants to present their questions and gain new perspectives. To foster a more intimate learning environment, places will be limited and a nominal fee of $25 per session will apply (including breakfast). Meet the Professor tickets can be purchased during your registration process.
Thursday, March 31, 2022 - 1300 - 1330hrs
Thursday, March 31, 2022 - 07:00 - 07:45
Jean-Nicolas Vauthey MD; USA
MTP01 - Tumor Biology in CRLM
 - JN Vauthey - Photo.jpg)
Dr. Vauthey is Professor of Surgery Chief of the Hepato-Pancreato-Biliary Section and the Dallas/Fort Worth Living Legend Chair of Cancer Research . Dr. Vauthey’s clinical research focuses on methods to measure and to improve outcome after hepatic resection for hepatobiliary malignancies. Dr. Vauthey proposed a standardized method for calculating the volume of the anticipated liver remnant prior to major liver resection. This method of measurement is used to compare patients prior to extended liver resection to determine the need for preoperative portal vein embolization. Dr. Vauthey created the International Cooperative Study Group for Hepatocellular Carcinoma. The group critically analyzed the staging system for hepatocellular carcinoma and questioned its complexity. Based on this work, the American Joint Committee on Cancer and the International Union Against Cancer adopted a new simplified staging system for hepatocellular carcinoma. Dr. Vauthey is the Chair of The American Joint Committee on Cancer Hepatobiliary and Pancreas Task Force for the 8th Edition of the Manual for Staging Cancer. Dr. Vauthey has evaluated the use of preoperative chemotherapy in the multidisciplinary treatment of patients with colorectal liver metastases. He is the author of a treatment algorithm for hepatic colorectal liver metastases. Dr. Vauthey most recent research focuses on the evaluation of the biology of colorectal liver metastases. Dr. Vauthey and his research team have shown that 6 mutated genes in 5 cancer pathways predict the outcome and prognosis of Stage IV colorectal cancer. These findings have implications for surgical treatment and surveillance after liver resection for liver metastases. Based on this work, the surgical approaches to patients with metastatic colorectal cancer can be personalized based on unique cancer biology features. Dr. Vauthey with his colleagues have recently developed a fast track treatment of colorectal liver metastases combining radiological and surgical procedures in a single hybrid room with state of the art surgical and imaging technology.
Dr. Vauthey has been an invited speaker at many major national and international meetings, including the postgraduate courses of the Society for Surgery of the Alimentary Tract, the American College of Surgeons, and the Society of Surgical Oncology. Dr. Vauthey organized and moderated symposia at national and international meetings (Society of Surgical Oncology, American College of Surgeons, International Hepato-Pancreato-Biliary Association). Dr. Vauthey is the Past President of the Americas Hepato-Pancreato-Biliary Association and the current President of the Society for Surgery of the Alimentary Tract the premier academic surgical society focusing on the study of digestive diseases. Dr. Vauthey co-authored more than 600 publications in peer-reviewed journals and more than 85 reviews and book chapters in major textbooks. Dr. Vauthey is editor or co-editor of major textbook devoted to hepatobiliary and pancreatic cancers. Dr. Vauthey organized and chaired Consensus Conferences on Colorectal Liver Metastases and Resectable and Borderline Resectable Pancreas Cancer jointly sponsored by the American Hepato-Pancreato-Biliary Association, Society for Surgery of the Alimentary Tract, and Society of Surgical Oncology. Dr. Vauthey is a reviewer for major surgical and medical journals. He is on the editorial board of major journals including the Journal of the American College of Surgeons and Annals of Surgery. Dr. Vauthey is Associate Editor of Digestive Surgery.
Dr. Vauthey is the recipient of multiple awards including the prestigious 2011 Faculty Achievement Award in Patient Care for his commitment to the mission of The University of Texas MD Anderson Cancer.
Cristina Ferrone MD; USA
MTP02 - Locally Advanced Pancreatic Cancer
 - C Ferrone - Photo.jpg)
Cristina R Ferrone is an Associate Professor of Surgery at the Massachusetts General Hospital and Harvard Medical School. She is the Surgical Director of the Liver Program and Associate Program Director for the General Surgery residency. She is also the Director of the Office of Clinical Careers for the MGH. She is the PI of the Phase III Alliance 21806 trial for patients with resectable pancreatic cancer.
Olivier Soubrane MD; France
MTP03 - Liver Resection in Patients with Portal Hypertension
Olivier Soubrane is Professor of Surgery and chairs the Department of Surgery in Institut Mutualiste Montsouris in Paris, France. He received his training in surgery in Paris, France, and a post-doc fellowship in liver transplantation with Prof. Carlos E. Esquivel in San Francisco, CA, USA. He previously chaired the Department of Surgery in Cochin Hospital, the Department of HPB Surgery in St Antoine
Hospital, and the Department of HPB Surgery and Liver transplantation in Beaujon Hospital, all in Paris, France.
He has dedicated a significant period in research, leading a surgical research laboratory for ten years in Cochin Hospital and serving two terms in Surgery Committees for INSERM, the French National Agency for Research.
As academic surgeon, Olivier Soubrane is Member of the Editorial Board of Annals of Surgery and invited reviewer for several international journals including Journal of Hepatology, Annals of Surgical Oncology, Transplantation, American Journal of Transplantation, and EBioMedicine.
His research interest includes liver cancer, laparoscopic and robotic techniques for resection of liver tumors and live donor hepatectomy. He has reported the first laparoscopic left lateral sectionectomy in a live donor with Daniel Cherqui in 2002 and the first laparoscopic right hepatectomy in a live donor in 2013.
Founding member of the International Laparoscopic Liver Society (ILLS), Olivier Soubrane was co-President with Daniel Cherqui of the first world meeting held in Paris on July 6-8, 2017.
Krishnakumar Madhavan MD; Singapore
MTP04 - HPB Surgery & Transplantation in COVID-19 Pandemic
 - KK Madhavan - Photo.jpg)
Prof Madhavan (KK) completed his medical studies and initial surgical training in India and subsequently moved to the United Kingdom where he completed Higher Surgical Training and was appointed Consultant General Surgeon at the Royal infirmary of Edinburgh in 1996. He remained in that post mainly as an HPB and liver, renal and pancreas transplant surgeon for the next 11 years. In 2007 he took up tenure at the National University of Singapore as Associate Professor and Senior Consultant Surgeon. In 2015 he was promoted to Full Professor at the University and has remained as Head of Departments of Surgery at National University Hospital and the YLL School of Medicine. More recently he took up the post of Group Director for Surgery at the National University Health System (NUHS).
He has held various leadership positions including President of the Society of Transplantation in Singapore and National Director for Liver transplantation in Singapore. He was nominated as Treasurer of A-PHPBA and served in that capacity till he was President-elect of A-PHPBA from 2019 to 2021. He has recently taken over as President of A-PHPBA (2021 – 2023) from Prof Christopher Christophi.
Antonio Pinna MD; USA
MTP05 - Split Liver Transplantation
 - A Pinna - Photo.jpg)
Antonio D. Pinna MD PhD, after a multiorgan transplant and HPB training at the University of Pittsburgh at the T.E. Starzl Transplant Institute and working as staff surgeons in transplant at the TE Starzl Transplant Insitute in Pittsburgh and at the Transplant Institute at the Univ. of Miami, became Professor of Surgery at the University of Modena (Italy) in 2000 where he started a new multiorgan transplant program especially dedicated to liver transplant (cadaveric and living donor) and multivisceral transplantation. In 2003 he became Professor of Surgery and Director of Transplant and general Surgery Dept. at the University of Bologna (Italy) S.Orsola Hospital. In 2017 Dr. Pinna moved to the Cleveland Clinic Abu Dhabi (UAE) where he developed the first multiorgan transplant center of the Emirates with particular attention in developing living donor liver transplantation. In 2020 he has been appointed as Center Director of the Abdominal Transplant Center and Florida Region of the Cleveland Clinic Florida. Pioneer in the field of transplantation, devoted to patient care and young surgeons training, Dr. Antonio Pinna main clinical and research interest has been in liver transplantation surgical technique, post-transplant management of complications, multivisceral transplant and intestinal rescue surgery and treatment of HCC and liver metastases. He has been appointed as chairman of the European Surgical Association Program Committee (2014 – 2022). He is reviewer or Assistant Editor of many peer review medical journals especially Annals of Surgery and Journal of Hepatology. He is member of many surgical Association and presently Professor of Clinical Surgery at the Florida Atlantic University.
Nancy Ascher MD; USA
MTP06 - Biliary Complications in Liver Transplantation
Dr. Nancy Ascher has devoted her career to organ transplantation and transplant research. She is the first woman to have performed a liver transplant and has inspired many women in the medical field, especially in transplantation. She completed her undergraduate and medical education at the University of Michigan, Ann Arbor; and completed her general surgery residency and clinical transplantation fellowship at the University of Minnesota, where she later joined the faculty and became Clinical Director of the Liver Transplant Program. Dr. Ascher was recruited by the UCSF Department of Surgery and served as the Department Chair for 17 years.
Dr. Ascher is a fellow of the American College of Surgeons. She is a member of numerous other medical societies, including the Transplantation Society and the American Society of Transplant Surgeons, both of which she has served as President. She has also served on the Presidential Task Force on Organ Transplantation, Surgeon General's Task Force on Increasing Donor Organs, and Secretary of Health and Human Services Advisory Committee on Organ Transplantation. Dr. Ascher is currently a member of the WHO Taskforce on Donation and Transplantation of Human Organs and Tissues.
John Windsor MD; New Zealand
MTP07 - Acute Pancreatitis
 - J Windsor - Photo.png)
John Windsor grew up in the Indian Himalayas, did surgical training in New Zealand and specialist HBP training in Edinburgh. Professor of Surgery and Director of Surgical and Translational Research Centre, University of Auckland. HBP and Upper GI Surgeon at the Auckland City and Mercy Hospitals. Fellow of ANZ, American and Edinburgh Colleges of Surgeons. Yeoh Ghim Seng Professor at National University of Singapore. Has been Secretary General of International Hepato-Pancreato-Biliary Association and Chair Section of Academic Surgery in the RACS. For 30 years he has been active in promoting research and education, especially the training of surgeon scientists. His surgical interests include the management of acute and chronic pancreatitis, pancreatic cancer, and gastro-oesophageal reflux and cancer. His research includes pathophysiology of acute pancreatitis, the role of toxic mesenteric lymph in critical illness and the mapping and modulation of gastric electrical activity. He has published widely with a GS H-index of 77. Awarded Gluckman Medal for distinguished research contributions at the University of Auckland, the Sir Louis Barnett Medal for distinguished contributions to the RACS and elected Fellow of the American Surgical Association, James IV Association and the Royal Society of New Zealand.
Thursday, March 31, 2022 - 1300 - 1330hrs
Thursday, March 31, 2022 - 07:00 - 07:45
Jean-Nicolas Vauthey MD; USA
MTP01 - Tumor Biology in CRLM
Yuman Fong MD
Dr. Yuman Fong is a graduate of Brown University (BA, Medieval Literature, 1981) and Cornell University Medical College (MD, 1984). He is the Sangiacomo Chair and Chairman of the Department of Surgery at the City of Hope Medical Center.
Dr. Fong is best known clinically for his extensive work in the field of liver and pancreatic surgery––especially for pioneering many laparoscopic, robotic and ablative therapies for these cancers. He has assisted in the design and deployment of many novel surgical tools.
Dr. Fong has also been active in biologic bench investigation. His early research was in immune activation during cancer or infection. He was part of the group that discovered tumor necrosis factor and helped established the field of innate immunity. His laboratory focus over the last 15 years has been in the field of gene therapy, designing and studying the use of genetically modified viruses for the killing of cancer. His group was the first to administer recombinant viruses into the blood stream of man as a cancer treatment. His leadership in this field on the national level has included serving as the Chair of the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health.
He has co-authored over 700 peer reviewed articles and 12 text books. He has served on the editorial boards of 14 journals, and is currently Editor-in-Chief of Molecular Therapy Oncolytics (Cell Press).
Cristina Ferrone MD; USA
MTP02 - Locally Advanced Pancreatic Cancer
Julie Heimbach MD
Julie Heimbach is a Professor of Surgery and the Chair of Division of Transplantation at the Mayo Clinic College of Medicine in Rochester, MN. She has dedicated a significant amount of time to UNOS, having served on numerous committees as well as the Board of Directors, and most recently, as the chair of the liver-Intestine committee. Dr. Heimbach also recently served on the ASTS council and currently serves as an Associate Editor both for the American Journal of Transplantation, and for the Journal of Hepatology. Her clinical and research interests include liver transplantation for hepatobiliary malignancies, living donor transplantation, and obesity in liver transplantation.
TBD
MTP03 - Liver Resection in Patients with Portal Hypertension
Andrea Schlegel MD
Andrea Schlegel is a certified Transplant and Hepatobiliary Surgeon, currently working at the Careggi University Hospital in Florence, Italy and the University Hospital in Zurich, Switzerland.
Andrea Schlegel grew up in Dresden, Germany, where she attended the Justus-von-Liebig University in Giessen, Germany, subsequently graduating in Medicine in 2007. She received her surgical training at University Hospital in Zurich, Switzerland, including a three-year postdoctoral research fellowship and completing her Chief Residency in 2015. She then moved to England to complete a fellowship in Hepatobiliary Surgery and Liver Transplantation at the Queen Elizabeth Hospital in Birmingham, where she then worked as a Consultant Surgeon, before returning to the Division of Abdominal Surgery and Transplantation at the University of Zurich. In 2020, she was recruited to build and support the translational research at the Careggi University Hospital in Florence, Italy with a focus on a comparative analyses of various machine perfusion techniques in transplantation of solid organs.
Since more than 10 years, her research focus on underlying mechanisms of ischemia/reperfusion injury and protective effects of machine perfusion technology. One of Dr. Schlegel`s main interest is the development of new markers to predict organ viability during perfusion, to enable the safe use of high-risk livers. One main topic her group focus on is the comparison of the mitochondrial metabolism in marginal livers during machine perfusion and transplantation.
Dr. Schlegel's clinical interests include liver transplantation and hepatobiliary surgery. Based on her work in Switzerland, England and Italy, she has developed significant clinical experience with the transplantation of risky livers and has developed new prediction models to improve outcomes based on improved donor-recipient matching. She is a co-author of over 120 journal articles and book chapters.
Krishnakumar Madhavan; Singapore
MTP04 - HPB Surgery & Transplantation in COVID-19 Pandemic
Andrea Schlegel MD
Andrea Schlegel is a certified Transplant and Hepatobiliary Surgeon, currently working at the Careggi University Hospital in Florence, Italy and the University Hospital in Zurich, Switzerland.
Andrea Schlegel grew up in Dresden, Germany, where she attended the Justus-von-Liebig University in Giessen, Germany, subsequently graduating in Medicine in 2007. She received her surgical training at University Hospital in Zurich, Switzerland, including a three-year postdoctoral research fellowship and completing her Chief Residency in 2015. She then moved to England to complete a fellowship in Hepatobiliary Surgery and Liver Transplantation at the Queen Elizabeth Hospital in Birmingham, where she then worked as a Consultant Surgeon, before returning to the Division of Abdominal Surgery and Transplantation at the University of Zurich. In 2020, she was recruited to build and support the translational research at the Careggi University Hospital in Florence, Italy with a focus on a comparative analyses of various machine perfusion techniques in transplantation of solid organs.
Since more than 10 years, her research focus on underlying mechanisms of ischemia/reperfusion injury and protective effects of machine perfusion technology. One of Dr. Schlegel`s main interest is the development of new markers to predict organ viability during perfusion, to enable the safe use of high-risk livers. One main topic her group focus on is the comparison of the mitochondrial metabolism in marginal livers during machine perfusion and transplantation.
Dr. Schlegel's clinical interests include liver transplantation and hepatobiliary surgery. Based on her work in Switzerland, England and Italy, she has developed significant clinical experience with the transplantation of risky livers and has developed new prediction models to improve outcomes based on improved donor-recipient matching. She is a co-author of over 120 journal articles and book chapters.
Antonio Pinna MD; USA
MTP05 - Split Liver Transplantation
Yuman Fong MD
Dr. Yuman Fong is a graduate of Brown University (BA, Medieval Literature, 1981) and Cornell University Medical College (MD, 1984). He is the Sangiacomo Chair and Chairman of the Department of Surgery at the City of Hope Medical Center.
Dr. Fong is best known clinically for his extensive work in the field of liver and pancreatic surgery––especially for pioneering many laparoscopic, robotic and ablative therapies for these cancers. He has assisted in the design and deployment of many novel surgical tools.
Dr. Fong has also been active in biologic bench investigation. His early research was in immune activation during cancer or infection. He was part of the group that discovered tumor necrosis factor and helped established the field of innate immunity. His laboratory focus over the last 15 years has been in the field of gene therapy, designing and studying the use of genetically modified viruses for the killing of cancer. His group was the first to administer recombinant viruses into the blood stream of man as a cancer treatment. His leadership in this field on the national level has included serving as the Chair of the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health.
He has co-authored over 700 peer reviewed articles and 12 text books. He has served on the editorial boards of 14 journals, and is currently Editor-in-Chief of Molecular Therapy Oncolytics (Cell Press).
Nancy Ascher MD; USA
MTP06 - Biliary Complications in Liver Transplantation
Julie Heimbach MD
Julie Heimbach is a Professor of Surgery and the Chair of Division of Transplantation at the Mayo Clinic College of Medicine in Rochester, MN. She has dedicated a significant amount of time to UNOS, having served on numerous committees as well as the Board of Directors, and most recently, as the chair of the liver-Intestine committee. Dr. Heimbach also recently served on the ASTS council and currently serves as an Associate Editor both for the American Journal of Transplantation, and for the Journal of Hepatology. Her clinical and research interests include liver transplantation for hepatobiliary malignancies, living donor transplantation, and obesity in liver transplantation.
John Windsor MD; New Zealand
MTP07 - Acute Pancreatitis
Andrea Schlegel MD
Andrea Schlegel is a certified Transplant and Hepatobiliary Surgeon, currently working at the Careggi University Hospital in Florence, Italy and the University Hospital in Zurich, Switzerland.
Andrea Schlegel grew up in Dresden, Germany, where she attended the Justus-von-Liebig University in Giessen, Germany, subsequently graduating in Medicine in 2007. She received her surgical training at University Hospital in Zurich, Switzerland, including a three-year postdoctoral research fellowship and completing her Chief Residency in 2015. She then moved to England to complete a fellowship in Hepatobiliary Surgery and Liver Transplantation at the Queen Elizabeth Hospital in Birmingham, where she then worked as a Consultant Surgeon, before returning to the Division of Abdominal Surgery and Transplantation at the University of Zurich. In 2020, she was recruited to build and support the translational research at the Careggi University Hospital in Florence, Italy with a focus on a comparative analyses of various machine perfusion techniques in transplantation of solid organs.
Since more than 10 years, her research focus on underlying mechanisms of ischemia/reperfusion injury and protective effects of machine perfusion technology. One of Dr. Schlegel`s main interest is the development of new markers to predict organ viability during perfusion, to enable the safe use of high-risk livers. One main topic her group focus on is the comparison of the mitochondrial metabolism in marginal livers during machine perfusion and transplantation.
Dr. Schlegel's clinical interests include liver transplantation and hepatobiliary surgery. Based on her work in Switzerland, England and Italy, she has developed significant clinical experience with the transplantation of risky livers and has developed new prediction models to improve outcomes based on improved donor-recipient matching. She is a co-author of over 120 journal articles and book chapters.
Thursday, March 31, 2022 - 1300 - 1330hrs
Thursday, March 31, 2022 - 07:00 - 07:45
Jean-Nicolas Vauthey MD; USA
MTP01 - Tumor Biology in CRLM
Yuman Fong MD
Dr. Yuman Fong is a graduate of Brown University (BA, Medieval Literature, 1981) and Cornell University Medical College (MD, 1984). He is the Sangiacomo Chair and Chairman of the Department of Surgery at the City of Hope Medical Center.
Dr. Fong is best known clinically for his extensive work in the field of liver and pancreatic surgery––especially for pioneering many laparoscopic, robotic and ablative therapies for these cancers. He has assisted in the design and deployment of many novel surgical tools.
Dr. Fong has also been active in biologic bench investigation. His early research was in immune activation during cancer or infection. He was part of the group that discovered tumor necrosis factor and helped established the field of innate immunity. His laboratory focus over the last 15 years has been in the field of gene therapy, designing and studying the use of genetically modified viruses for the killing of cancer. His group was the first to administer recombinant viruses into the blood stream of man as a cancer treatment. His leadership in this field on the national level has included serving as the Chair of the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health.
He has co-authored over 700 peer reviewed articles and 12 text books. He has served on the editorial boards of 14 journals, and is currently Editor-in-Chief of Molecular Therapy Oncolytics (Cell Press).
Cristina Ferrone MD; USA
MTP02 - Locally Advanced Pancreatic Cancer
Julie Heimbach MD
Julie Heimbach is a Professor of Surgery and the Chair of Division of Transplantation at the Mayo Clinic College of Medicine in Rochester, MN. She has dedicated a significant amount of time to UNOS, having served on numerous committees as well as the Board of Directors, and most recently, as the chair of the liver-Intestine committee. Dr. Heimbach also recently served on the ASTS council and currently serves as an Associate Editor both for the American Journal of Transplantation, and for the Journal of Hepatology. Her clinical and research interests include liver transplantation for hepatobiliary malignancies, living donor transplantation, and obesity in liver transplantation.
TBD
MTP03 - Liver Resection in Patients with Portal Hypertension
Andrea Schlegel MD
Andrea Schlegel is a certified Transplant and Hepatobiliary Surgeon, currently working at the Careggi University Hospital in Florence, Italy and the University Hospital in Zurich, Switzerland.
Andrea Schlegel grew up in Dresden, Germany, where she attended the Justus-von-Liebig University in Giessen, Germany, subsequently graduating in Medicine in 2007. She received her surgical training at University Hospital in Zurich, Switzerland, including a three-year postdoctoral research fellowship and completing her Chief Residency in 2015. She then moved to England to complete a fellowship in Hepatobiliary Surgery and Liver Transplantation at the Queen Elizabeth Hospital in Birmingham, where she then worked as a Consultant Surgeon, before returning to the Division of Abdominal Surgery and Transplantation at the University of Zurich. In 2020, she was recruited to build and support the translational research at the Careggi University Hospital in Florence, Italy with a focus on a comparative analyses of various machine perfusion techniques in transplantation of solid organs.
Since more than 10 years, her research focus on underlying mechanisms of ischemia/reperfusion injury and protective effects of machine perfusion technology. One of Dr. Schlegel`s main interest is the development of new markers to predict organ viability during perfusion, to enable the safe use of high-risk livers. One main topic her group focus on is the comparison of the mitochondrial metabolism in marginal livers during machine perfusion and transplantation.
Dr. Schlegel's clinical interests include liver transplantation and hepatobiliary surgery. Based on her work in Switzerland, England and Italy, she has developed significant clinical experience with the transplantation of risky livers and has developed new prediction models to improve outcomes based on improved donor-recipient matching. She is a co-author of over 120 journal articles and book chapters.
Krishnakumar Madhavan; Singapore
MTP04 - HPB Surgery & Transplantation in COVID-19 Pandemic
Andrea Schlegel MD
Andrea Schlegel is a certified Transplant and Hepatobiliary Surgeon, currently working at the Careggi University Hospital in Florence, Italy and the University Hospital in Zurich, Switzerland.
Andrea Schlegel grew up in Dresden, Germany, where she attended the Justus-von-Liebig University in Giessen, Germany, subsequently graduating in Medicine in 2007. She received her surgical training at University Hospital in Zurich, Switzerland, including a three-year postdoctoral research fellowship and completing her Chief Residency in 2015. She then moved to England to complete a fellowship in Hepatobiliary Surgery and Liver Transplantation at the Queen Elizabeth Hospital in Birmingham, where she then worked as a Consultant Surgeon, before returning to the Division of Abdominal Surgery and Transplantation at the University of Zurich. In 2020, she was recruited to build and support the translational research at the Careggi University Hospital in Florence, Italy with a focus on a comparative analyses of various machine perfusion techniques in transplantation of solid organs.
Since more than 10 years, her research focus on underlying mechanisms of ischemia/reperfusion injury and protective effects of machine perfusion technology. One of Dr. Schlegel`s main interest is the development of new markers to predict organ viability during perfusion, to enable the safe use of high-risk livers. One main topic her group focus on is the comparison of the mitochondrial metabolism in marginal livers during machine perfusion and transplantation.
Dr. Schlegel's clinical interests include liver transplantation and hepatobiliary surgery. Based on her work in Switzerland, England and Italy, she has developed significant clinical experience with the transplantation of risky livers and has developed new prediction models to improve outcomes based on improved donor-recipient matching. She is a co-author of over 120 journal articles and book chapters.
Antonio Pinna MD; USA
MTP05 - Split Liver Transplantation
Yuman Fong MD
Dr. Yuman Fong is a graduate of Brown University (BA, Medieval Literature, 1981) and Cornell University Medical College (MD, 1984). He is the Sangiacomo Chair and Chairman of the Department of Surgery at the City of Hope Medical Center.
Dr. Fong is best known clinically for his extensive work in the field of liver and pancreatic surgery––especially for pioneering many laparoscopic, robotic and ablative therapies for these cancers. He has assisted in the design and deployment of many novel surgical tools.
Dr. Fong has also been active in biologic bench investigation. His early research was in immune activation during cancer or infection. He was part of the group that discovered tumor necrosis factor and helped established the field of innate immunity. His laboratory focus over the last 15 years has been in the field of gene therapy, designing and studying the use of genetically modified viruses for the killing of cancer. His group was the first to administer recombinant viruses into the blood stream of man as a cancer treatment. His leadership in this field on the national level has included serving as the Chair of the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health.
He has co-authored over 700 peer reviewed articles and 12 text books. He has served on the editorial boards of 14 journals, and is currently Editor-in-Chief of Molecular Therapy Oncolytics (Cell Press).
Nancy Ascher MD; USA
MTP06 - Biliary Complications in Liver Transplantation
Julie Heimbach MD
Julie Heimbach is a Professor of Surgery and the Chair of Division of Transplantation at the Mayo Clinic College of Medicine in Rochester, MN. She has dedicated a significant amount of time to UNOS, having served on numerous committees as well as the Board of Directors, and most recently, as the chair of the liver-Intestine committee. Dr. Heimbach also recently served on the ASTS council and currently serves as an Associate Editor both for the American Journal of Transplantation, and for the Journal of Hepatology. Her clinical and research interests include liver transplantation for hepatobiliary malignancies, living donor transplantation, and obesity in liver transplantation.
John Windsor MD; New Zealand
MTP07 - Acute Pancreatitis
Andrea Schlegel MD
Andrea Schlegel is a certified Transplant and Hepatobiliary Surgeon, currently working at the Careggi University Hospital in Florence, Italy and the University Hospital in Zurich, Switzerland.
Andrea Schlegel grew up in Dresden, Germany, where she attended the Justus-von-Liebig University in Giessen, Germany, subsequently graduating in Medicine in 2007. She received her surgical training at University Hospital in Zurich, Switzerland, including a three-year postdoctoral research fellowship and completing her Chief Residency in 2015. She then moved to England to complete a fellowship in Hepatobiliary Surgery and Liver Transplantation at the Queen Elizabeth Hospital in Birmingham, where she then worked as a Consultant Surgeon, before returning to the Division of Abdominal Surgery and Transplantation at the University of Zurich. In 2020, she was recruited to build and support the translational research at the Careggi University Hospital in Florence, Italy with a focus on a comparative analyses of various machine perfusion techniques in transplantation of solid organs.
Since more than 10 years, her research focus on underlying mechanisms of ischemia/reperfusion injury and protective effects of machine perfusion technology. One of Dr. Schlegel`s main interest is the development of new markers to predict organ viability during perfusion, to enable the safe use of high-risk livers. One main topic her group focus on is the comparison of the mitochondrial metabolism in marginal livers during machine perfusion and transplantation.
Dr. Schlegel's clinical interests include liver transplantation and hepatobiliary surgery. Based on her work in Switzerland, England and Italy, she has developed significant clinical experience with the transplantation of risky livers and has developed new prediction models to improve outcomes based on improved donor-recipient matching. She is a co-author of over 120 journal articles and book chapters.
Thursday, March 31, 2022 - 1300 - 1330hrs
Friday, April 1, 2022 - 07:00 - 07:45
Steven Strasberg MD; USA
MTP08 - Management of Bile Duct Injury
Steven Strasberg is a graduate of the University of Toronto Medical School and the Gallie Course in Surgery. He was an attending surgeon at the University of Toronto rising to the position of Professor of Surgery. He was the founding director of the Surgical Scientist Program. In 1992 he moved to Washington University in Saint Louis, USA, where he became Pruett Professor of Surgery and founding head of the Section of HPB Surgery. He is a Past President of AHPBA and twice appointed a member of the Executive Council of IHPBA. In 2018 he was awarded the Medallion for the Advancement of Surgical Care by The American Surgical Association. He is also recipient of the Lifetime Achievement Award of the IHPBA, and the Distinguished Service Award of the AHPBA. He is an honorary member of JHPBS. He has published over 300 peer reviewed papers and 50 book chapters and has held grants from the Medical Research Council of Canada and the National Institutes of Health in the USA. His current interest areas are avoidance and management of biliary injury, classification and quantification of surgical complications, and development of novel anatomic approaches in HPB surgery.
Chinnusamy Palanivelu MD; India
MTP09 - Robotic Pancreas Resection
• President of Association of Surgeons of India
• Founder President of Association of Minimal Access Surgeons of India
• President of Indian Society for Diseases of Esophagus and Stomach
• Managing Trustee of GEM Medical Foundation
Revolutionary Surgeon
• First to introduce Laparoscopic Surgery in South India. He is instrumental in developing advanced laparoscopic surgery, including cancer.
• Keyhole surgery is less morbid and faster recovery, most wanted for Indian people, where 80% are in agriculture or labourers.
• Developed newer technique making it cost effective and affordable by all people, irrespective of socioeconomic strata.
DR. B.C. Roy National Awards
• 2008 -Recognising best talent under the category of Specialty Development of Medicine, namely laparoscopic surgery
• 2015 -Awarded as "Eminent Medical Person" category, the highest category for medical.
Highly Reputed World Famous Surgeon
• International Olympic Silver Medal Winner: First Indian to win Silver Medal in the International Olympic Surgery Competition in Keyhole Surgery held at Phoenix, USA, jointly organised by American and Japanese Society in 2009.
• The Award of Fellowship Ad-Hominum: The highest honour of the a Royal College of Surgeons of Edinburgh in 2004.
• Doctorate of Health Sciences (PhD): Anglia Ruskin Chelmsford University, Cambridge, UK in 2014.
• Living Legend of Laparoscopy Surgery, by City Council of New York.
• Honorari Causa by San American University, Lima Peru, the oldest University (1551 ).
• Essex Medical Society (EMS) Annual Award of House of Commons, UK Parliament, 2018.
• Visiting Professor to many Universities across the globe.
William Jarnagin MD; USA
MTP10 - Hepatic Artery Chemotherapy
Dr. William R. Jarnagin was raised outside of Boston, Massachusetts and earned his undergraduate degree in chemistry from Dartmouth College in 1982, a Master’s degree in chemistry from Brandeis University in 1984 and an MD from Rush Medical College in 1988. He completed his training in general surgery at the University of California, San Francisco in 1996. From 1990-93, he completed a research fellowship at the Liver Center Laboratory at San Francisco General Hospital. From 1996-97, he served as the Hepatobiliary Fellow at Memorial Sloan-Kettering Cancer Center (MSKCC). Since 1997, he has been an attending surgeon at Memorial Sloan-Kettering Cancer Center, where he has served as Chief of the Hepatopancreatobiliary Service since 2008 and was a Vice-Chairman of the Department of Surgery from 2006-2010. He holds the Leslie H. Blumgart, M.D. Chair in Surgical Oncology and is Professor of Surgery at Weill Medical College of Cornell University.
Dr. Jarnagin’s research has focused on genomics, novel therapies and biomarkers of treatment response in patients with biliary tract cancer, intraoperative navigation systems, and improvements in intraoperative management during major liver and pancreas resection. He has authored or co-authored over 500 articles in peer-reviewed journals, over 75 book chapters or invited reviews and has co-edited four textbooks. He serves as the senior editor of ‘Blumgart’s Surgery of the Liver, Biliary Tract and Pancreas.’ He has served as the HPB Section Editor for Annals of Surgical Oncology and is a member of the editorial boards of the Journal of the American College of Surgeons, HPB and the European Journal of Surgical Research. In addition to the IHPBA and AHPBA, he is a member of several surgical societies, including SUS and ASA. He was a member of the AHPBA Executive Council for over 10 years, serving as the Program Chair (2007-08), Treasurer (2009-11), President (2011-2012), and he currently serves as President-elect of the IHPBA.
Hugo Pinto Marques MD; Portugal
MTP11 - Domino Liver Transplantation
Hugo Pinto Marques is the Head of the department of General Surgery at Hepato-Biliary-Pancreatic and Transplantation Centre / Central Lisbon Hospital and University Centre, in Lisbon, Portugal. He is also Professor of Surgery at NOVA Medical School in Lisbon, as well as an Hepatobiliary Surgeon at CUF Tejo Hospital and Principal Investigator at CEDOC, Chronic Diseases Research Center, in Lisbon. He is currently Vice-President of the Portuguese Surgical Society, Secretary General of Les Compagnons Hépato-Biliaires, and Chair of the Advisory Membership Committee of the European Surgical Association. Hugo Pinto Marques is also founding member and Portuguese representative of the International Laparoscopic Liver Society and the European Registry of Minimally Invasive Liver Surgery. Main clinical areas of interest are Liver Surgery and Liver Transplantation, domino liver transplantation, perihilar cholangiocarcinoma, extreme liver surgery, laparoscopic liver surgery and robotic liver surgery. Current research interests include the use of biomarkers in liver transplantation.
Susan Orloff MD; USA
MTP12 - Polycystic Liver Disease
 - S Orloff - Photo.png)
Susan L. Orloff, MD, FACS, FAASLD is Professor of Surgery, Chief, Division of Abdominal Organ Transplantation/Hepatobiliary Surgery, Adjunct Professor, Department of Molecular Microbiology & Immunology at OHSU, is an internationally recognized leader in liver transplantation/hepatobiliary surgery, and has been Fellowship Director of OHSU’s AHPBA-Accredited HPB Fellowship Program since 2012.
She attended medical school, internship in internal medicine, and then embarked on a career in surgery at UCSF via a general surgery residency, and was awarded an NIH research training grant. Following GS residency, she pursued a multi-organ transplantation fellowship at UCSF. In 1995, she was recruited to Oregon Health & Sciences University (OHSU), and Portland VA Medical Center in the Division of Abdominal Organ Transplantation/Hepatobiliary Surgery. She was appointed Chief, of the Division and Director of the Portland VA Transplant Program in 2008. She has a busy clinical practice in abdominal multi-organ transplantation/hepatobiliary surgery.
Dr. Orloff’s clinical research interests include epidemiology/screening/treatments/genomics of HCC, and other facets of liver transplantation. She runs an NIH-funded laboratory with continuous NIH and/or VA Merit Review funding for 26 years, studying immunologic tolerance, and mechanisms/genomics of CMV-accelerated allograft rejection in heart and kidney transplant rodent models. She was previously Vice-Chair of Research for the Department of Surgery at OHSU.
Dr. Orloff has served on numerous institutional/local/regional/national/international committees and societies. She has authored over 130 peer-reviewed scientific articles, 25 book chapters, and served as Co-editor for a HPB/Transplantation Textbook, and is on the editorial board of 3 journals.
Dr. Orloff’s commitment to the future of transplantation in the US and globally is foremost in her values and mission, as the transplant community navigates optimizing and expanding the pool of potential donors, as well as determining best strategess to minimize disparities in access to organ transplantation, optimizing outcomes and life years benefit.
Masaru Miyazaki MD; Japan
MTP13 - Surgical Margins in Biliary Tumors
Masaru Miyazaki graduated from Chiba University in 1975, and trained at General Surgery of the First Department Chiba University till 1981.He had been to Toronto as a surgical research fellow from 1981 to 1983 Department of Surgery, University of Toronto. He was appointed as an assistant professor of Department of General Surgery, Chiba University in 1983, and also as an associate professor in 1993. He was appointed to Chairman Professor in 2001. In 2011 he was also appointed as Director of Chiba University Hospital and the Vice-President of Chiba University. In 2016 he moved to the director of Mita Hospital in Tokyo and also vice President of International University of Health & Welfare. Since 2020, he has been the director of Narita Hospital in Chiba. He hosted 112th Annual meeting of Japan Surgical Society in 2012, also 49th Annual meeting of Japan Biliary Society in 2013, as the congress president. As a visiting Professor, he had visited; Louisville University, US in 1996, Yonsei University, Korea in 2003, Sanjay Gandhi Post-Graduate Institute (SGPGIMS), India in 2005, Cincinnati University, US in 2010 and Belgrade University, Serbia in 2018. He was nominated as an Honorary membership of; Egyptian Society of Surgeons 2010, European Surgical Association 2014, American Surgical Association 2017, and Brazilian Society of Surgical Oncology (BSSO) 2015.
Christos Dervenis MD; Greece
MTP14 - Surgery for Chronic Pancreatitis
Christos Dervenis, MD, PhD, FRCS, is holding the position of Professor of Surgery at the Medical School University of Cyprus and he is also Head of the Department of Surgical Oncology and HPB Surgery at Metropolitan Hospital in Greece. . In addition, he has served as a visiting Professor of Surgery to several international academic institutes, including the Mayo Clinic Medical School, Rochester, MN and Yale University, CT USA; the University of Lund, Sweden; the University of Verona, Italy; and the University of the Witwatersrand in Johannesburg, South Africa.
Professor Dervenis has served as President of the EAHPB Association and the Hellenic HPB Association. He was also on the board of the International Hepato-Pancreato-Biliary Association (IHPBA). He has been vice president of the HPB division of the European Union of Medical Specialists (UEMS) and President of the European Digestive Surgery. In addition, Professor Dervenis was, and he still is, member of the editorial boards in number of scientific journals including British Journal of Surgery, Pancreatology, the IHPBA journal HPB, and HPB Surgery.
Professor Dervenis is the editor of 3 books in the field of HPB surgery and has published over 220 papers in peer-reviewed journals, with about 40000 citations and h-index of 70. His main clinical interests include surgery of the pancreas and liver, nutrition, and oncology.
Thursday, March 31, 2022 - 1300 - 1330hrs
Saturday, April 2, 2022 - 07:00 - 07:45
Masayuki Ohtsuka MD; Japan
MTP15 - Hilar Cholangiocarcinoma
I graduated from School of Medicine, Chiba University in 1988. After receiving general surgery training at Department of General Surgery, Chiba University Hospital and affiliated hospitals, I entered Graduate School of Medicine, Chiba University and majored surgical pathology at Department of Molecular Pathology under Professor Kondo. I had been to Belgium as a research fellow from 1996 to 2000 under Professor Gianello, Department of Experimental Surgery at Louvain Catholic University. I returned to Department of General Surgery, Chiba University in 2000 as a staff under Professor Miyazaki, and promoted to Professor and Chairman in 2016.
I have been an active member in many surgical and HBP societies. I am currently an Associate editor for Journal of Hepato-Biliary-Pancreatic Sciences (JHBPS).
My clinical interest is HBP surgery for both benign and malignant diseases, adult liver transplantation, and HBP surgical pathology.
Ellen Hagopian MD; USA
MTP16 - Models of HPB Training
Ellen J. Hagopian, MD, MHPE, FSSO, FACS is a board-certified General Surgeon specializing in liver, pancreas, biliary tract, gallbladder, and upper gastrointestinal tract surgery. Dr. Hagopian completed her General Surgery Residency at Columbia-Presbyterian Medical Center in New York followed by a Fellowship in Laparoscopic Surgery at New York Medical College. Focusing her skill in Hepatobiliary Surgery, she completed a two-year fellowship in Hepatobiliary Surgery in Paris at Le Centre Hépato-Biliaire. She has been honored by the Pr. Henri Bismuth as a member of les Compagnons Hépatobiliaires.
In addition to her clinical work, Dr. Hagopian is the inaugural Surgery Clerkship Director at Hackensack Meridian Medical School of Medicine. Both regional and nationally, she is a recognized leader in HPB surgical ultrasound training for surgeons and trainees. She holds the positions of Chair of the American College of Surgeons National Ultrasound Faculty and Co-Chair of the Education and Training Committee of AHPBA, in addition to serving as Associate Editor for HPB. Her research interests are focused in surgical education, including surgical ultrasound curriculum and assessment.
Eduardo de Santibanes MD; Argentina
MTP17 - ALPPS
.jpg)
Eduardo de Santibañes MD, PhD, FACS (hon), ASA (Hon), ESA (hon)
Full Prof. in Surgery University of Buenos Aires
Chairman Liver Transplant Unit Hospital Italiano Buenos Aires
Member Academia Nacional de Medicina Argentina
Michael Kendrick MD; USA
MTP18 - Laparoscopic Pancreatoduodenectomy
Dr. Michael Kendrick is Chair of the Department of Surgery at the Mayo Clinic in Rochester, Minnesota. He is Chair of the Rochester Surgical & Procedural Subcommittee and Interim Chair of the Mayo Clinic Surgical & Procedural Committee. He holds the academic rank of Professor of Surgery, Mayo Clinic College of Medicine and Science, and he is a consultant in the Division of Hepatobiliary and Pancreas Surgery. Doctor Kendrick received his M.D. degree from George Washington University in Washington, DC. He completed his general surgery residency at the Mayo Clinic College of Medicine in Rochester, Minnesota. After residency, he received additional training as a Mayo Foundation Scholar in hepatobiliary surgery (Mayo Clinic Rochester and Paris, France) and in minimally invasive surgery (Mount Sinai, New York). His clinical interests include innovative and advanced minimally invasive approaches for treatment of pancreatic and hepatobiliary diseases. Doctor Kendrick has published 20 book chapters and 193 peer-reviewed articles. He has been recognized by his trainees and has received “Teacher of the Year in Surgery” several times. He has served on multiple society and institutional committees including previous roles as Vice Chair of the Rochester Personnel Committee and Vice Chair of the Rochester Surgical and Procedural and Committee.
Kyung-Suk Suh MD; Korea
MTP19 - Minimally Invasive Living Donor Liver Transplantation
Prof. Kyung-Suk Suh is a Professor of Department of Surgery, Seoul National University College of Medicine.
Prof. Suh graduated from Seoul National University College of Medicine with his medical degree in 1984 and completed his internship and residency in Department of Surgery at Seoul National University Hospital, receiving his diploma in General Surgery in 1989.
Since 1993, Prof. Suh held a number of professional positions at the Seoul National University Hospital in Seoul, including instructor, assistant Prof., associate Prof., Prof., chairman of Department of Surgery Seoul national university College of Medicine, Chief of Seoul National University Hospital Transplant Center and Director of Seoul National University Cancer Hospital.
Since 2011, Prof. Suh have been taking a number of roles, including Chairman in Korean Association of HBP Surgery(2015-2017), President of the International Living Donor Liver Transplantation Study Group(2015-2017), Chairman of Korean Surgical Society(2016-2018), President of Korean Surgical Society(2020-2021 ) and Chairman of Korean Association of the Study of the Liver.
Prof. Suh’s major fields of interest are Liver Transplantation, Oncological Surgery for Hepato-biliary Carcinoma and minimal invasive surgery.
Wojciech Polak MD; Netherlands
MTP20 - DCD Liver Transplantation
Wojciech Polak graduated in medicine cum laude at the Medical University in Wroclaw (Poland) in 1992. Between 1992 and 1993 he finished his internship in Klinikum Innestadt in Munich, Germany. In 2000 he finished his residency in general surgery at the Department of Vascular, General and Transplantation Surgery at the University Hospital in Wroclaw, where he was appointed afterwards as a consultant surgeon. Between 2001 and 2003 he completed surgical fellowship in hepatobiliary surgery and liver transplantation at the Department of Surgery at the University Medical Center in Groningen, the Netherlands. In 2006 he was appointed as a consultant surgeon in hepatobiliary and transplant surgery at the Department of Surgery at the University Medical Center in Groningen. Since 2007 he is certified transplant surgeon at the European Board of Surgeons. In 2008 he defended his PhD thesis entitled “Technical aspects of liver transplantation” at the University of Groningen. The same year he was appointed as Associated Professor at the Medical University in Wroclaw. Since September 2009 Dr. Wojciech Polak is currently appointed as a consultant transplant and hepatobiliary surgeon at the Department of Surgery at the Erasmus MC, University Medical Center Rotterdam, the Netherlands, where he is Surgical Director of Liver Transplant Program.
Between 2007 and 2018 Dr. Wojciech Polak was actively working in the Education Committee of the ESOT, where he served as the Vice-Chair. Between 2019 and 2021 he was a Chair of European Liver and Intestine Transplant Association (ELITA), where he currently served as a Past Chair. In 2015 he was awarded with Honorary Diploma of European Board of Surgery (UEMS) in Hepatopancreatobiliary Surgery. Dr. Polak is also the Chair of the Education Committee of the European-African Hepatopancreatobiliary Association. His clinical and scientific area of expertise is liver transplantation and hepatobiliary surgery.
Marc Besselink MD; Netherlands
MTP21 - Total Pancreatectomy
Marc Besselink (1976) is the professor of Pancreatic and Hepatobiliary (HPB) surgery at Amsterdam. UMC, University of Amsterdam, the Netherlands. He studied at Utrecht University (Medicine) and Oxford University (Evidence Based Health Care). In 2002, he co-founded the Dutch Pancreatitis Study Group, in 2012 the Dutch Pancreatic Cancer Group, and in 2016 the European Consortium on Minimally Invasive Pancreatic Surgery. He was trained as a surgeon in Utrecht, Amsterdam, and Southampton. Marc has designed and coordinated multiple randomized controlled multicenter trials in acute pancreatitis and pancreatic cancer. He is the current chair of the scientific committee of the Dutch Pancreatic Cancer Group and Dutch Pancreatic Cancer Audit, Dutch Pancreas Biobank. Marc is the 2021-2022 President-Elect of EAHPBA and the Chairman of the Innovation sub-committee of IHPBA. You can follow Marc on Twitter @MarcBesselink.